Metformina Viatris (Metformin Hydrochloride)

Metformin reduces blood glucose primarily by inhibiting hepatic gluconeogenesis, which lowers the amount of glucose produced by the liver. It also increases peripheral insulin sensitivity through activation of AMP‑activated protein kinase, enhancing glucose uptake in muscle and fat tissues without stimulating insulin secretion.

The exact dose of Metformina Viatris is individualized. A qualified prescriber determines the appropriate strength, frequency, and titration schedule based on the patient’s clinical condition, renal function, and response to therapy.

Metformina Viatris is classified as Pregnancy Category B, indicating that animal studies have not shown risk but adequate human data are lacking. It may be used during pregnancy if the potential benefit justifies the risk. Use while breastfeeding should be discussed with a healthcare professional, as small amounts are excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metformina Viatris belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors. Unlike sulfonylureas, metformin does not stimulate insulin release, reducing the risk of hypoglycemia. It also offers weight‑neutral or modest weight‑loss effects, whereas some other classes may cause weight gain.

Metformina Viatris should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister or container, protect them from moisture, humidity, and direct sunlight. Do not store in a refrigerator or freezer.

Metformina Viatris is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious adverse events are lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, and severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Prompt medical attention is required if symptoms of these conditions appear.

Metformina Viatris is contraindicated in patients with known hypersensitivity to metformin or other biguanides, in those with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in patients receiving radiographic contrast studies without appropriate discontinuation of the drug.